Cisplatin ototoxicity

Hearing Loss: Classification, Causes and Treatment

Volumn , Issue , 2011, Pages 39-63

  Ding, Dalian ^a   Allman, Brian ^a   Yin, Shankai ^b   Sun, Hong ^c   Salvi, Richard ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867894450     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (142)

1. Adam, M., Bayer, C., Henke, J., Grosu, A., Molls, M., & Nieder, C. (2008). Tirapazamine plus cisplatin and irradiation in a mouse model: improved tumor control at the cost of increased toxicity. J Cancer Res Clin Oncol, 134(2), 137-146. doi: 10.1007/s00432-007-0260-7
2. Aguilar-Markulis, N. V., Beckley, S., Priore, R., & Mettlin, C. (1981). Auditory toxicity effects of long-term cis-dichlorodiammineplatinum II therapy in genitourinary cancer patients. J Surg Oncol, 16(2), 111-123.
3. Alam, S. A., Ikeda, K., Oshima, T., Suzuki, M., Kawase, T., Kikuchi, T., & Takasaka, T. (2000). Cisplatin-induced apoptotic cell death in Mongolian gerbil cochlea. Hear Res, 141(1-2), 28-38.
4. Allan, S. G., & Smyth, J. F. (1986). Small intestinal mucosal toxicity of cis-platinum--comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer, 53(3), 355-360.
5. Aris, S. M., Gewirtz, D. A., Ryan, J. J., Knott, K. M., & Farrell, N. P. (2007). Promotion of DNA strand breaks, interstrand cross-links and apoptotic cell death in A2780 human ovarian cancer cells by transplatinum planar amine complexes. Biochem Pharmacol, 73(11), 1749-1757. doi: S0006-2952(07)00132-3 [pii] 10.1016/j.bcp.2007.02.013
6. Bae, I. H., Kang, S. W., Yoon, S. H., & Um, H. D. (2006). Cellular components involved in the cell death induced by cisplatin in the absence of p53 activation. Oncol Rep, 15(5), 1175-1180.
7. Barry, M. A., Behnke, C. A., & Eastman, A. (1990). Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol, 40(10), 2353-2362.
8. Berg, A. L., Spitzer, J. B., & Garvin, J. H., Jr. (1999). Ototoxic impact of cisplatin in pediatric oncology patients. Laryngoscope, 109(11), 1806-1814. doi: 10.1097/00005537-199911000-00016
9. Black, F. O., Myers, E. N., Schramm, V. L., Johnson, J., Sigler, B., Thearle, P. B., & Burns, D. S. (1982). Cisplatin vestibular ototoxicity: preliminary report. Laryngoscope, 92(12), 1363-1368.
10. Blakley, B. W., Gupta, A. K., Myers, S. F., & Schwan, S. (1994). Risk factors for ototoxicity due to cisplatin. Arch Otolaryngol Head Neck Surg, 120(5), 541-546.
11. Boogerd, W., ten Bokkel Huinink, W. W., Dalesio, O., Hoppenbrouwers, W. J., & van der Sande, J. J. (1990). Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement. J Neurooncol, 9(3), 255-263.
12. Brock, P. R., Bellman, S. C., Yeomans, E. C., Pinkerton, C. R., & Pritchard, J. (1991). Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol, 19(4), 295-300.
13. Buyukcelik, A., Onur, H., Akbulut, H., Bulent, Y., Ensari, A., Utkan, G., Icli, F. (2005). Expression of p53 protein and DNA flow cytometry in gastric adenocarcinoma: implications in patients treated with adjuvant etoposide, adriamycin and cisplatin. Tumori, 91(4), 302-308.
14. Campbell, K. C., Rybak, L. P., Meech, R. P., & Hughes, L. (1996). D-methionine provides excellent protection from cisplatin ototoxicity in the rat. Hear Res, 102(1-2), 90-98.
15. Canetta, R., Rozencweig, M., & Carter, S. K. (1985). Carboplatin: the clinical spectrum to date. Cancer Treat Rev, 12 Suppl A, 125-136.
16. Cardinaal, R. M., de Groot, J. C., Huizing, E. H., Veldman, J. E., & Smoorenburg, G. F. (2000a). Dose-dependent effect of 8-day cisplatin administration upon the morphology of the albino guinea pig cochlea. Hear Res, 144(1-2), 135-146. doi: S0378-5955(00)00059-9 [pii]
17. Cardinaal, R. M., de Groot, J. C., Huizing, E. H., Veldman, J. E., & Smoorenburg, G. F. (2000b). Histological effects of co-administration of an ACTH((4-9)) analogue, ORG 2766, on cisplatin ototoxicity in the albino guinea pig. Hear Res, 144(1-2), 157-167.
18. Carpenter, A. M., Muchow, D., & Goycoolea, M. V. (1989). Ultrastructural studies of the human round window membrane. Arch Otolaryngol Head Neck Surg, 115(5), 585-590.
19. Castello, R., Alegria, E., Merino, A., Fidalgo, M. L., & Martinez-Caro, D. (1990). The value of exercise testing in patients with coronary artery spasm. Am Heart J, 119(2 Pt 1), 259-263.
20. Caussanel, J. P., Levi, F., Brienza, S., Misset, J. L., Itzhaki, M., Adam, R., Mathe, G. (1990). Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst, 82(12), 1046-1050.
21. Cavaletti, G., Bogliun, G., Marzorati, L., Tredici, G., Colombo, N., Parma, G., & Miceli, M. D. (1994). Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res, 14(3B), 1287-1292.
22. Cavaletti, G., Minoia, C., Schieppati, M., & Tredici, G. (1994). Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys, 29(4), 771-776.
23. Cepero, V., Garcia-Serrelde, B., Moneo, V., Blanco, F., Gonzalez-Vadillo, A. M., Alvarez-Valdes, A., Carnero, A. (2007). Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription. Clin Transl Oncol, 9(8), 521-530. doi: 1077 [pii]
24. Chen, G., Cao, P., & Goeddel, D. V. (2002). TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90. Mol Cell, 9(2), 401-410. doi: S1097276502004501 [pii]
25. Chu, G. (1994). Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem, 269(2), 787-790.
26. Clerici, W. J., Hensley, K., DiMartino, D. L., & Butterfield, D. A. (1996). Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res, 98(1-2), 116-124.
27. Culmsee, C., Zhu, X., Yu, Q. S., Chan, S. L., Camandola, S., Guo, Z., Mattson, M. P. (2001). A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem, 77(1), 220-228.
28. DeHaan, R. D., Yazlovitskaya, E. M., & Persons, D. L. (2001). Regulation of p53 target gene expression by cisplatin-induced extracellular signal-regulated kinase. Cancer Chemother Pharmacol, 48(5), 383-388.
29. Dehne, N., Lautermann, J., Petrat, F., Rauen, U., & de Groot, H. (2001). Cisplatin ototoxicity: involvement of iron and enhanced formation of superoxide anion radicals. Toxicol Appl Pharmacol, 174(1), 27-34.
30. Devarajan, P., Savoca, M., Castaneda, M. P., Park, M. S., Esteban-Cruciani, N., Kalinec, G., & Kalinec, F. (2002). Cisplatin-induced apoptosis in auditory cells: role of death receptor and mitochondrial pathways. Hear Res, 174(1-2), 45-54.
31. Dilling, J. M., Nakashima, T., & Snow, J. B., Jr. (1973). Effect of ethacrynic acid on endolymphatic DC potential. Arch Otolaryngol, 98(3), 183-186.
32. Ding, D., Jiang, H., McFadden, H., & Salvi, R. J. (2004). Ethacrynic acid is the key for opening of the blood-labyrinth barrier Chinese Journal of Otology, 1(2), 42-47.
33. Ding, D., Jiang, H., Wang, P., & Salvi, R. (2007). Cell death after co-administration of cisplatin and ethacrynic acid. Hear Res, 226(1-2), 129-139. doi: S0378-5955(06)00190-0 [pii]10.1016/j.heares.2006.07.015
34. Ding, D., McFadden, S. L., & Salvi, R. J. (2001). Cochlear hair cell densities and inner ear staining techniques. In J. Willott (Ed.), The auditory psychobiology of the mouse (pp. 189-204). Boca Raton: CRC Press.
35. Ding, D., McFadden, S. L., Woo, J. M., & Salvi, R. J. (2002). Ethacrynic acid rapidly and selectively abolishes blood flow in vessels supplying the lateral wall of the cochlea. Hear Res, 173(1-2), 1-9. doi: S0378595502005853 [pii]
36. Ding, D., Qi, W., ZHang, M., Wang, P., Jiang, H., & Salvi, R. (2008). Cisplatin and its ototoxicity. Chinese Journal of Otology, 6(2), 125-133.
37. Ding, D., & Salvi, R. (2004). Review of cellular changes in the cochlea due to aminoglycoside antibiotics. The Volta Review, 105(3), 407-438.
38. Ding, D., Stracher, A., & Salvi, R. J. (2002). Leupeptin protects cochlear and vestibular hair cells from gentamicin ototoxicity. Hear Res, 164(1-2), 115-126. doi: S0378595501004178 [pii]
39. Ding, D., Wang, P., Jiang, H., Coling, D., Salvi, R. (2009). Gene expression in cisplatin ototoxicity and protection with p53 inhibitor. Chinese Journal of Otology, 4(2), 15-24.
40. Ding, D. L., Wang, J., Salvi, R., Henderson, D., Hu, B. H., McFadden, S. L., & Mueller, M. (1999). Selective loss of inner hair cells and type-I ganglion neurons in carboplatin-treated chinchillas. Mechanisms of damage and protection. Ann. N. Y. Acad. Sci., 884, 152-170.
41. Dunaway, G., Mhaskar, Y., Armour, G., Whitworth, C., & Rybak, L. (2003). Migration of cochlear lateral wall cells. Hear Res, 177(1-2), 1-11. doi: S0378595502007670 [pii]
42. Eastman, A. (1986). Reevaluation of interaction of cis-dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry, 25(13), 3912-3915.
43. Estrem, S. A., Babin, R. W., Ryu, J. H., & Moore, K. C. (1981). Cis-diamminedi-chloroplatinum (II) ototoxicity in the guinea pig. Otolaryngol Head Neck Surg, 89(4), 638-645.
44. Gabaizadeh, R., Staecker, H., Liu, W., Kopke, R., Malgrange, B., Lefebvre, P. P., & Van de Water, T. R. (1997). Protection of both auditory hair cells and auditory neurons from cisplatin induced damage. Acta Otolaryngol, 117(2), 232-238.
45. Gao, W. Q., Dybdal, N., Shinsky, N., Murnane, A., Schmelzer, C., Siegel, M., Winslow, J. W. (1995). Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol, 38(1), 30-37. doi: 10.1002/ana.410380108
46. Germann, N., Brienza, S., Rotarski, M., Emile, J. F., Di Palma, M., Musset, M., Misset, J. L. (1999). Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol, 10(3), 351-354.
47. Goycoolea, M. V. (1992). The round window membrane under normal and pathological conditions. Acta Otolaryngol Suppl, 493, 43-55.
48. Goycoolea, M. V., Carpenter, A. M., & Muchow, D. (1987). Ultrastructural studies of the round-window membrane of the cat. Arch Otolaryngol Head Neck Surg, 113(6), 617-624.
49. Gratton, M. A., & Kamen, B. A. (1990). Potentiation of cisplatin ototoxicity by noise. J Clin Oncol, 8(12), 2091-2092.
50. Hanada, K., Asano, K., Nishimura, T., Chimata, T., Matsuo, Y., Tsuchiya, M., & Ogata, H. (2008). Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats. J Pharm Pharmacol, 60(3), 317-322. doi: 10.1211/jpp.60.3.0006
51. Hanigan, M. H., Gallagher, B. C., Taylor, P. T., Jr., & Large, M. K. (1994). Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res, 54(22), 5925-5929.
52. Hatzopoulos, S., Di Stefano, M., Campbell, K. C., Falgione, D., Ricci, D., Rosignoli, M., Martini, A. (2001). Cisplatin ototoxicity in the Sprague Dawley rat evaluated by distortion product otoacoustic emissions. Audiology, 40(5), 253-264.
53. He, J., Yin, S., Wang, J., Ding, D., & Jiang, H. (2009). Effectiveness of different approaches for establishing cisplatin-induced cochlear lesions in mice. Acta Otolaryngol, 1-9. doi: 914483463 [pii] 10.1080/00016480902856604
54. Helson, L., Okonkwo, E., Anton, L., & Cvitkovic, E. (1978). cis-Platinum ototoxicity. Clin Toxicol, 13(4), 469-478. doi: 10.3109/15563657808988252
55. Hershberger, P. A., McGuire, T. F., Yu, W. D., Zuhowski, E. G., Schellens, J. H., Egorin, M. J., Johnson, C. S. (2002). Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol Cancer Ther, 1(10), 821-829.
56. Hinojosa, R., Riggs, L. C., Strauss, M., & Matz, G. J. (1995). Temporal bone histopathology of cisplatin ototoxicity. Am J Otol, 16(6), 731-740.
57. Hofstetter, P., Ding, D., Powers, N., & Salvi, R. J. (1997). Quantitative relationship of carboplatin dose to magnitude of inner and outer hair cell loss and the reduction in distortion product otoacoustic emission amplitude in chinchillas. Hear. Res., 112(1-2), 199-215.
58. Jordan, P., & Carmo-Fonseca, M. (2000). Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci, 57(8-9), 1229-1235.
59. Jung, M., Hotter, G., Vinas, J. L., & Sola, A. (2009). Cisplatin upregulates mitochondrial nitric oxide synthase and peroxynitrite formation to promote renal injury. Toxicol Appl Pharmacol, 234(2), 236-246. doi: S0041-008X(08)00455-9 [pii] 10.1016/j.taap.2008. 10.014
60. Kaltenbach, J. A., Rachel, J. D., Mathog, T. A., Zhang, J., Falzarano, P. R., & Lewandowski, M. (2002). Cisplatin-induced hyperactivity in the dorsal cochlear nucleus and its relation to outer hair cell loss: relevance to tinnitus. J Neurophysiol, 88(2), 699-714.
61. Kamimura, T., Whitworth, C. A., & Rybak, L. P. (1999). Effect of 4-methylthiobenzoic acid on cisplatin-induced ototoxicity in the rat. Hear Res, 131(1-2), 117-127.
62. Kasajima, K., Kaneko, Y., & Ouchi, J. (1978). Changes of the stria vascularis induced by ethacrynic acid. Auris Nasus Larynx, 5(1), 1-16.
63. Kastan, M. B., Canman, C. E., & Leonard, C. J. (1995). P53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev, 14(1), 3-15.
64. Kaur, T., Khanduja, K. L., Kaushik, T., Kaushik, G., Gupta, R., Gupta, N. M., & Vaiphei, K. (2006). P53, COX-2, iNOS protein expression changes and their relationship with anti-oxidant enzymes in surgically and multi-modality treated esophageal carcinoma patients. J Chemother, 18(1), 74-84.
65. Klis, S. F., O'Leary, S. J., Hamers, F. P., De Groot, J. C., & Smoorenburg, G. F. (2000). Reversible cisplatin ototoxicity in the albino guinea pig. Neuroreport, 11(3), 623-626.
66. Klis, S. F., O'Leary, S. J., Wijbenga, J., de Groot, J. C., Hamers, F. P., & Smoorenburg, G. F. (2002). Partial recovery of cisplatin-induced hearing loss in the albino guinea pig in relation to cisplatin dose. Hear Res, 164(1-2), 138-146.
67. Kobayashi, H., Ohashi, N., Watanabe, Y., & Mizukoshi, K. (1987). Clinical features of cisplatin vestibulotoxicity and hearing loss. ORL J Otorhinolaryngol Relat Spec, 49(2), 67-72.
68. Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V., & Gudkov, A. V. (1999). A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science, 285(5434), 1733-1737.
69. Komarova, E. A., & Gudkov, A. V. (2001). Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors. Biochem Pharmacol, 62(6), 657-667.
70. Konishi, T., Gupta, B. N., & Prazma, J. (1983). Ototoxicity of cis-dichlorodiammine platinum (II) in guinea pigs. Am J Otolaryngol, 4(1), 18-26.
71. Kopelman, J., Budnick, A. S., Sessions, R. B., Kramer, M. B., & Wong, G. Y. (1988). Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. Laryngoscope, 98(8 Pt 1), 858-864. doi: 10.1288/00005537-198808000-00014
72. Kusakari, J., Ise, I., Comegys, T. H., Thalmann, I., & Thalmann, R. (1978). Effect of ethacrynic acid, furosemide, and ouabain upon the endolymphatic potential and upon high energy phosphates of the stria vascularis. Laryngoscope, 88(1 Pt 1), 12-37.
73. Lakkaraju, A., Dubinsky, J. M., Low, W. C., & Rahman, Y. E. (2001). Neurons are protected from excitotoxic death by p53 antisense oligonucleotides delivered in anionic liposomes. J Biol Chem, 276(34), 32000-32007.
74. Lang, H., Schulte, B. A., & Schmiedt, R. A. (2003). Effects of chronic furosemide treatment and age on cell division in the adult gerbil inner ear. J Assoc Res Otolaryngol, 4(2), 164-175.
75. Laurell, G., Andersson, A., Engstrom, B., & Ehrsson, H. (1995). Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemother Pharmacol, 36(1), 83-86.
76. Laurell, G., & Bagger-Sjoback, D. (1991). Dose-dependent inner ear changes after i.v. administration of cisplatin. J Otolaryngol, 20(3), 158-167.
77. Laurell, G., & Engstrom, B. (1989). The combined effect of cisplatin and furosemide on hearing function in guinea pigs. Hear Res, 38(1-2), 19-26. doi: 0378-5955(89)90124-X [pii]
78. Laurell, G., Engstrom, B., Hirsch, A., & Bagger-Sjoback, D. (1987). Ototoxicity of cisplatin. Int J Androl, 10(1), 359-362.
79. Laurell, G., Viberg, A., Teixeira, M., Sterkers, O., & Ferrary, E. (2000). Blood-perilymph barrier and ototoxicity: an in vivo study in the rat. Acta Otolaryngol, 120(7), 796-803.
80. Laurent, G., Erickson, L. C., Sharkey, N. A., & Kohn, K. W. (1981). DNA cross-linking and cytotoxicity induced by cis-diamminedichloroplatinum(II) in human normal and tumor cell lines. Cancer Res, 41(9 Pt 1), 3347-3351.
81. Lee, J. E., Nakagawa, T., Kita, T., Kim, T. S., Iguchi, F., Endo, T., Ito, J. (2004). Mechanisms of apoptosis induced by cisplatin in marginal cells in mouse stria vascularis. ORL J Otorhinolaryngol Relat Spec, 66(3), 111-118.
82. Leitao, D. J., & Blakley, B. W. (2003). Quantification of sodium thiosulphate protection on cisplatin-induced toxicities. J Otolaryngol, 32(3), 146-150.
83. Li, G., Sha, S. H., Zotova, E., Arezzo, J., Van de Water, T., & Schacht, J. (2002). Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest, 82(5), 585-596.
84. Maltzman, W., & Czyzyk, L. (1984). UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol, 4(9), 1689-1694.
85. Martins, N. M., Santos, N. A., Curti, C., Bianchi, M. L., & Santos, A. C. (2008). Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl Toxicol, 28(3), 337-344. doi: 10.1002/jat.1284
86. McAlpine, D., & Johnstone, B. M. (1990). The ototoxic mechanism of cisplatin. Hear Res, 47(3), 191-203.
87. McDonald, E. S., & Windebank, A. J. (2002). Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis, 9(2), 220-233. doi: 10.1006/nbdi.2001.0468 S0969996101904681 [pii]
88. McKeage, M. J. (1995). Comparative adverse effect profiles of platinum drugs. Drug Saf, 13(4), 228-244.
89. Melamed, S. B., Kaltenbach, J. A., Church, M. W., Burgio, D. L., & Afman, C. E. (2000). Cisplatin-induced increases in spontaneous neural activity in the dorsal cochlear nucleus and associated outer hair cell loss. Audiology, 39(1), 24-29.
90. Minami, S. B., Sha, S. H., & Schacht, J. (2004). Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear Res, 198(1-2), 137-143.
91. More, S. S., Akil, O., Ianculescu, A. G., Geier, E. G., Lustig, L. R., & Giacomini, K. M. (2010). Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci, 30(28), 9500-9509. doi: 30/28/9500 [pii] 10.1523/JNEUROSCI.1544-10.2010
92. Moroso, M. J., & Blair, R. L. (1983). A review of cis-platinum ototoxicity. J Otolaryngol, 12(6), 365-369.
93. Murray, D., Jenkins, W. T., & Meyn, R. E. (1985). Kinetics of DNA cross-linking in normal and neoplastic mouse tissues following treatment with cis-diamminedichloroplatinum(II) in vivo. Cancer Res, 45(12 Pt 1), 6446-6452.
94. Nakai, Y., Konishi, K., Chang, K. C., Ohashi, K., Morisaki, N., Minowa, Y., & Morimoto, A. (1982). Ototoxicity of the anticancer drug cisplatin. An experimental study. Acta Otolaryngol, 93(3-4), 227-232.
95. Palacios, G., & Moll, U. M. (2006). Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo. Oncogene, 25(45), 6133-6139.
96. Park, H. H., & Wu, H. (2006). Crystal structure of RAIDD death domain implicates potential mechanism of PIDDosome assembly. J Mol Biol, 357(2), 358-364.
97. Park, S. A., Choi, K. S., Bang, J. H., Huh, K., & Kim, S. U. (2000). Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand. J Neurochem, 75(3), 946-953.
98. Park, S. A., Park, H. J., Lee, B. I., Ahn, Y. H., Kim, S. U., & Choi, K. S. (2001). Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res, 93(1), 18-26.
99. Portilla, D., Li, S., Nagothu, K. K., Megyesi, J., Kaissling, B., Schnackenberg, L., Beger, R. D. (2006). Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int, 69(12), 2194-2204. doi: 5000433 [pii] 10.1038/sj.ki.5000433
100. Rabik, C., & Dolan, M. (2007). Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev, 33(1), 9-23.
101. Reyes, S., Ding, D., Sun, W., & Salvi, R. (2001). Effect of inner and outer hair cell lesions on electrically evoked otoacoustic emissions. Hear Res, 158(1-2), 139-150. doi: S0378595501003094 [pii]
102. Rosenberg, B., Vancamp, L., & Krigas, T. (1965). Inhibition of Cell Division in Escherichia Coli by Electrolysis Products from a Platinum Electrode. Nature, 205, 698-699.
103. Rosenberg, B., VanCamp, L., Trosko, J. E., & Mansour, V. H. (1969). Platinum compounds: a new class of potent antitumour agents. Nature, 222(5191), 385-386.
104. Ryan, A., Dallos, P., & McGee, T. (1979). Psychophysical tuning curves and auditory thresholds after hair cell damage in the chinchilla. J Acoust Soc Am, 66(2), 370-378.
105. Rybak, L. P., Mukherjea, D., Jajoo, S., & Ramkumar, V. (2009). Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med, 219(3), 177-186. doi: JST.JSTAGE/tjem/219.177 [pii]
106. Rybak, L. P., Whitworth, C., & Somani, S. (1999). Application of antioxidants and other agents to prevent cisplatin ototoxicity. Laryngoscope, 109(11), 1740-1744.
107. Salt, A. N., & Plontke, S. K. (2009). Principles of local drug delivery to the inner ear. Audiol Neurootol, 14(6), 350-360. doi: 000241892 [pii] 10.1159/000241892
108. Salvesen, G. S., & Dixit, V. M. (1997). Caspases: intracellular signaling by proteolysis. Cell, 91(4), 443-446. doi: S0092-8674(00)80430-4 [pii]
109. Sax, J. K., & El-Deiry, W. S. (2003). Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem, 278(38), 36435-36444.
110. Schaefer, S. D., Post, J. D., Close, L. G., & Wright, C. G. (1985). Ototoxicity of low- and moderate-dose cisplatin. Cancer, 56(8), 1934-1939.
111. Schaefer, S. D., Wright, C. G., Post, J. D., & Frenkel, E. P. (1981). Cis-platinum vestibular toxicity. Cancer, 47(5), 857-859.
112. Schweitzer, V. G. (1993). Ototoxicity of chemotherapeutic agents. Otolaryngol Clin North Am, 26(5), 759-789.
113. Schweitzer, V. G., Dolan, D. F., Abrams, G. E., Davidson, T., & Snyder, R. (1986). Amelioration of cisplatin-induced ototoxicity by fosfomycin. Laryngoscope, 96(9 Pt 1), 948-958.
114. Schweitzer, V. G., Rarey, K. E., Dolan, D. F., Abrams, G., Litterst, C. J., & Sheridan, C. (1986). Ototoxicity of cisplatin vs. platinum analogs CBDCA (JM-8) and CHIP (JM-9). Otolaryngol Head Neck Surg, 94(4), 458-470.
115. Sergi, B., Ferraresi, A., Troiani, D., Paludetti, G., & Fetoni, A. R. (2003). Cisplatin ototoxicity in the guinea pig: vestibular and cochlear damage. Hear Res, 182(1-2), 56-64.
116. Seth, R., Yang, C., Kaushal, V., Shah, S. V., & Kaushal, G. P. (2005). p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem, 280(35), 31230-31239. doi: M503305200 [pii] 10.1074/jbc.M503305200
117. Sheppard, W. M., Wanamaker, H. H., Pack, A., Yamamoto, S., & Slepecky, N. (2004). Direct round window application of gentamicin with varying delivery vehicles: a comparison of ototoxicity. Otolaryngol Head Neck Surg, 131(6), 890-896. doi: S0194599804013609 [pii] 10.1016/j.otohns.2004.05.021
118. Silverstein, H. (1999). Use of a new device, the MicroWick, to deliver medication to the inner ear. Ear Nose Throat J, 78(8), 595-598, 600.
119. Simon, T., Hero, B., Dupuis, W., Selle, B., & Berthold, F. (2002). The incidence of hearing impairment after successful treatment of neuroblastoma. Klin Padiatr, 214(4), 149-152. doi: 10.1055/s-2002-33179
120. Skinner, R. (2004). Best practice in assessing ototoxicity in children with cancer. Eur J Cancer, 40(16), 2352-2354. doi: S0959-8049(04)00615-X [pii] 10.1016/j.ejca.2004.08. 002
121. Sluyter, S., Klis, S. F., de Groot, J. C., & Smoorenburg, G. F. (2003). Alterations in the stria vascularis in relation to cisplatin ototoxicity and recovery. Hear Res, 185(1-2), 49-56. doi: S0378595503002600 [pii]
122. So, H., Kim, H., Lee, J. H., Park, C., Kim, Y., Kim, E., Park, R. (2007). Cisplatin cytotoxicity of auditory cells requires secretions of proinflammatory cytokines via activation of ERK and NF-kappaB. J Assoc Res Otolaryngol, 8(3), 338-355. doi: 10.1007/s10162-007-0084-9
123. Steyger, P. S. (2009). Potentiation of Chemical Ototoxicity by Noise. Semin Hear, 30(1), 38-46. doi: 10.1055/s-0028-1111105
124. Strauss, M., Towfighi, J., Lord, S., Lipton, A., Harvey, H. A., & Brown, B. (1983). Cis-platinum ototoxicity: clinical experience and temporal bone histopathology. Laryngoscope, 93(12), 1554-1559.
125. Tange, R. A. (1984). Differences in the cochlear degeneration pattern in the guinea pig as a result of gentamicin and cis-platinum intoxication. Clin Otolaryngol Allied Sci, 9(6), 323-327.
126. Tange, R. A., & Vuzevski, V. D. (1984). Changes in the stria vascularis of the guinea pig due to cis-platinum. Arch Otorhinolaryngol, 239(1), 41-47.
127. Tong, Q. S., Zheng, L. D., Wang, L., Zeng, F. Q., Chen, F. M., Dong, J. H., & Lu, G. C. (2005). Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther, 12(5), 509-514.
128. Tsukasaki, N., Whitworth, C. A., & Rybak, L. P. (2000). Acute changes in cochlear potentials due to cisplatin. Hear Res, 149(1-2), 189-198.
129. Uehara, T., Watanabe, H., Itoh, F., Inoue, S., Koshida, H., Nakamura, M., Maruyama, T. (2005). Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol, 79(8), 451-460. doi: 10.1007/s00204-005-0648-6
130. van Ruijven, M. W., de Groot, J. C., & Smoorenburg, G. F. (2004). Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res, 197(1-2), 44-54.
131. Wajant, H., Pfizenmaier, K., & Scheurich, P. (2003). Tumor necrosis factor signaling. Cell Death Differ, 10(1), 45-65. doi: 10.1038/sj.cdd.4401189 4401189 [pii]
132. Wang, J., Powers, N. L., Hofstetter, P., Trautwein, P., Ding, D., & Salvi, R. (1997). Effects of selective inner hair cell loss on auditory nerve fiber threshold, tuning and spontaneous and driven discharge rate. Hear. Res., 107(1-2), 67-82.
133. Wang, Y., Sun, X., Wu, J., Xu, B. E., Gu, C., Wang, H., Luo, Y. (2008). Casein kinase 1alpha interacts with RIP1 and regulates NF-kappaB activation. Biochemistry, 47(1), 441-448.
134. Watanabe, K., Inai, S., Jinnouchi, K., Baba, S., & Yagi, T. (2003). Expression of caspase-activated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated guinea pigs. Auris Nasus Larynx, 30(3), 219-225.
135. Watanabe, K., Inai, S., Jinnouchi, K., Bada, S., Hess, A., Michel, O., & Yagi, T. (2002). Nuclear-factor kappa B (NF-kappa B)-inducible nitric oxide synthase (iNOS/NOS II) pathway damages the stria vascularis in cisplatin-treated mice. Anticancer Res, 22(6C), 4081-4085.
136. Wei, Q., Dong, G., Yang, T., Megyesi, J., Price, P. M., & Dong, Z. (2007). Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol, 293(4), F1282-1291. doi: 00230.2007 [pii] 10.1152/ajprenal.00230.2007
137. Witte, M. C., & Kasperbauer, J. L. (2000). Round window membrane permeability to transforming growth factor-alpha: an in vitro study. Otolaryngol Head Neck Surg, 123(1 Pt 1), 91-96. doi: S0194-5998(00)76487-4 [pii] 10.1067/mhn.2000.106006
138. Wright, C. G., & Schaefer, S. D. (1982). Inner ear histopathology in patients treated with cis-platinum. Laryngoscope, 92(12), 1408-1413.
139. Zhang, M., Liu, W., Ding, D., & Salvi, R. (2003). Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience, 120(1), 191-205.
140. Zheng, J. L., & Gao, W. Q. (1996). Differential damage to auditory neurons and hair cells by ototoxins and neuroprotection by specific neurotrophins in rat cochlear organotypic cultures. Eur J Neurosci, 8(9), 1897-1905.
141. Zhou, Y., Ding, D., Kraus, K. S., Yu, D., & Salvi, R. J. (2009). Functional and structural changes in the chinchilla cochlea and vestibular system following round window application of carboplatin. Audiol Med, 7(4), 189-199. doi: 10.3109/16513860903335795
142. Zorbas, H., & Keppler, B. K. (2005). Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? Chembiochem, 6(7), 1157-1166. doi: 10.1002/cbic.200400427